A Phase 3 interventional study of Ranibizumab (RFB002) and Laser in Diabetic Macular Edema and Visual Impairment, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-01.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing ranibizumab in Vision Disorders — none open to participants now, none under way, none of them phase 3. Ranibizumab · Vision Disorders.
Among the 26 studies testing ranibizumab in Vision Disorders, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 14 in phase 3, and was the 22nd registered.
361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.
Browse Vision Disorders studies →None of the 26 studies testing ranibizumab in Vision Disorders is open now. The open studies under Vision Disorders, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 384 is above the median of 75 across 245 interventional studies indexed under Vision Disorders.
Median enrollment 178 across the 26 interventional studies. Of the 22 that completed or were terminated, 19 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 26 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
32 studies in Vision Disorders by Novartis: none open now, none under way, none of them phase 3. Of 30 finished, 25 (83%) have results posted.
Among the 32 studies in Vision Disorders by Novartis, this one is the 7th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2014, is one of 17 in phase 3, and was the 18th registered.
Novartis’s Vision Disorders studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing ranibizumab in Vision Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 32 in Vision Disorders:
This tab as a report to print or save as PDF → With an account.
Study of efficacy and safety of 0.5 mg ranibizumab in Chinese patients with diabetic macular edema (DME)
The purpose of this study was to provide efficacy and safety data on 0.5 mg ranibizumab intravitreal injections compared to laser photocoagulation in Chinese patients with visual impairment due to DME. Treatment was driven by achieving vision stabilization.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 initial intravitreal injections to the study eye at Day 1, Month 1 and Month 2, followed by as-needed intravitreal injections of ranibizumab 0.5 mg guided by VA stabilization, plus sham laser
Drug: Ranibizumab (RFB002) · Procedure: Sham laser
Laser photocoagulation applied to the study eye at Day 1, followed by active laser photocoagulation at intervals no shorter than 3 months apart, plus sham injections
Procedure: Laser · Drug: Sham injection
Ranibizumab 0.5 mg/0.05 mL for intravitreal injection
Also known as: Lucentis
Laser photocoagulation according to Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines
Imitation of an intravitreal injection consisting of an empty vial and an injection syringe without a needle
Imitation of an active laser
Mean Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) (Letters) to Month 1 Through 12
Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. Twelve monthly BCVA values were averaged \[(Month1+Month2+...+Month12)/12\], and the baseline BCVA value was subtracted from the average. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Monthly from Month 1 through Month 12
Mean Change From Baseline in BCVA (Letters) at Each Visit
Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Monthly from Month 1 through Month 12
Mean Change From Baseline in Central Sub-Field Thickness (CSFT) at Each Visit
CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using Optical Coherence Tomography (OCT). A negative change value indicates an improvement in macular edema, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Monthly from Month 1 through Month 12
Percentage of Patients With BCVA Gain of ≥ 10 and ≥ 15 Letters From Baseline at Month 12
Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Month 12
Percentage of Patients With BCVA Loss of < 10 and < 15 Letters From Baseline to Month 12
Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Month 12
Percentage of Patients With BCVA ≥ 73 Letters at Month 12
Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. BCVA ≥ 73 letters is approximately equivalent to 20/40 on a Snellen chart. One eye (study eye) contributed to the analysis.
Time frame: Month 12
Mean Average Change in BCVA From Month 4 to Month 12 Compared to Month 3
Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. Nine monthly BCVA values were averaged \[(Month4+Month5+...+Month12)/9\],and the Month 3 BCVA value was subtracted from the average. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time frame: Monthly from Month 3 through Month 12
Mean Change From Baseline in Patient-Reported Visual Functioning at Month 6 and Month 12, Composite Score
Visual functioning was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in visual functioning, while a negative change value indicates a worsening.
Time frame: Baseline, Month 6, Month 12
Mean Change From Baseline in Patient-Reported General Health at Month 6 and Month 12
General health was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in general health, while a negative change value indicates a worsening.
Time frame: Baseline, Month 6, Month 12
Mean Change From Baseline in Patient-Reported General Vision at Month 6 and Month 12
General vision was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in general vision, while a negative change value indicates a worsening.
Time frame: Baseline, Month 6, Month 12
Mean Change From Baseline in Patient-Reported Color Vision at Month 6 and Month 12
Color vision was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in color vision, while a negative change value indicates a worsening.
Time frame: Baseline, Month 6, Month 12
Mean Change From Baseline in Patient-Reported Peripheral Vision at Month 6 and Month 12
Peripheral vision was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in peripheral vision, while a negative change value indicates a worsening.
Time frame: Baseline, Month 6, Month 12
Mean Change From Baseline in Patient-Reported Ocular Pain at Month 6 and Month 12
Ocular pain was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in ocular pain, while a negative change value indicates a worsening.
Time frame: Baseline, Month 6, Month 12
Mean Change From Baseline in Patient-Reported Near Activities at Month 6 and Month 12
Near activities were assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in near activities, while a negative change value indicates a worsening.
Time frame: Baseline, Month 6, Month 12
Mean Change From Baseline in Patient-Reported Distance Activities at Month 6 and Month 12
Distance activities were assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in distance activities, while a negative change value indicates a worsening.
Time frame: Baseline, Month 6, Month 12
Mean Change From Baseline in Patient-Reported Social Functioning at Month 6 and Month 12
Social functioning was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in social functioning, while a negative change value indicates a worsening.
Time frame: Baseline, Month 6, Month 12
Mean Change From Baseline in Patient-Reported Mental Health at Month 6 and Month 12
Mental health was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in mental health, while a negative change value indicates a worsening.
Time frame: Baseline, Month 6, Month 12
Mean Change From Baseline in Patient-Reported Roles Difficulties at Month 6 and Month 12
Roles difficulties were assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in roles difficulties, while a negative change value indicates a worsening.
Time frame: Baseline, Month 6, Month 12
Mean Change From Baseline in Patient-Reported Dependency at Month 6 and Month 12
Dependency was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in dependency, while a negative change value indicates a worsening.
Time frame: Baseline, Month 6, Month 12
Mean Change From Baseline in Patient-Reported Driving at Month 6 and Month 12
Driving was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in driving, while a negative change value indicates a worsening. Note: Many patients did not answer the driving related question as they did not drive at all.
Time frame: Baseline, Month 6, Month 12
Mean Number of Ranibizumab Re-treatments Received in the Study Eye From Month 3 Onward
A ranibizumab re-treatment was defined as an administration of ranibizumab injection at a scheduled visit following at least one non-missed visit where ranibizumab was not administered in the study eye due to visual acuity stabilization. This outcome measure was pre-specified for the Ranibizumab 0.5 mg arm only.
Time frame: Monthly from Month 3 through Month 12
| Milestone | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Started | 307 | 77 |
| Full analysis set | 307 | 77 |
| Treated (safety analysis set) | 307 | 75 |
| Completed | 279 | 63 |
| Not completed | 28 | 14 |
| Withdrew: Adverse event | 6 | 4 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Physician decision | 5 | 2 |
| Withdrew: Protocol deviation | 5 | 0 |
| Withdrew: Subject/guardian decision | 8 | 8 |
Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. Twelve monthly BCVA values were averaged \[(Month1+Month2+...+Month12)/12\], and the baseline BCVA value was subtracted from the average. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.
| letters | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Mean Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) (Letters) to Month 1 Through 12 | 6.8 ± 6.58 | 1.1 ± 7.73 |
Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.
| letters | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 1 | 4.0 ± 5.59 | -0.9 ± 5.50 |
| Change from Baseline at Month 2 | 5.8 ± 6.44 | 0.0 ± 8.08 |
| Change from Baseline at Month 3 | 6.9 ± 6.91 | 1.1 ± 9.18 |
| Change from Baseline at Month 4 | 6.6 ± 7.23 | 0.0 ± 11.64 |
| Change from Baseline at Month 5 | 6.8 ± 7.41 | 0.6 ± 10.61 |
| Change from Baseline at Month 6 | 6.8 ± 8.00 | 0.3 ± 11.01 |
| Change from Baseline at Month 7 | 6.8 ± 7.95 | 1.3 ± 10.13 |
| Change from Baseline at Month 8 | 7.4 ± 8.12 | 1.9 ± 9.69 |
| Change from Baseline at Month 9 | 7.3 ± 8.18 | 1.8 ± 9.33 |
| Change from Baseline at Month 10 | 7.2 ± 8.45 | 1.6 ± 9.23 |
| Change from Baseline at Month 11 | 7.8 ± 8.55 | 1.7 ± 9.35 |
| Change from Baseline at Month 12 | 7.8 ± 8.72 | 2.5 ± 8.78 |
CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using Optical Coherence Tomography (OCT). A negative change value indicates an improvement in macular edema, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.
| micrometers | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 1 | -126.7 ± 140.59 | -33.1 ± 113.34 |
| Change from Baseline at Month 2 | -141.3 ± 146.15 | -48.8 ± 133.22 |
| Change from Baseline at Month 3 | -154.2 ± 147.94 | -58.5 ± 157.30 |
| Change from Baseline at Month 4 | -130.4 ± 152.60 | -72.6 ± 149.13 |
| Change from Baseline at Month 5 | -141.0 ± 153.28 | -72.3 ± 150.45 |
| Change from Baseline at Month 6 | -146.2 ± 154.87 | -72.9 ± 152.47 |
| Change from Baseline at Month 7 | -138.4 ± 161.04 | -72.4 ± 150.86 |
| Change from Baseline at Month 8 | -146.9 ± 154.68 | -81.8 ± 151.89 |
| Change from Baseline at Month 9 | -142.4 ± 156.03 | -80.9 ± 157.69 |
| Change from Baseline at Month 10 | -137.6 ± 152.73 | -82.9 ± 166.16 |
| Change from Baseline at Month 11 | -144.8 ± 159.87 | -88.1 ± 170.11 |
| Change from Baseline at Month 12 | -146.5 ± 157.61 | -85.9 ± 166.60 |
Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.
| percentage of participants | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Gain of ≥ 10 letters | 40.6 | 20.0 |
| Gain of ≥ 15 letters | 18.5 | 8.0 |
Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.
| percentage of participants | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Loss of < 10 letters | 97.0 | 89.3 |
| Loss of <15 letters | 99.0 | 97.3 |
Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. BCVA ≥ 73 letters is approximately equivalent to 20/40 on a Snellen chart. One eye (study eye) contributed to the analysis.
| percentage of participants | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Percentage of Patients With BCVA ≥ 73 Letters at Month 12 | 36.0 | 21.3 |
Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. Nine monthly BCVA values were averaged \[(Month4+Month5+...+Month12)/9\],and the Month 3 BCVA value was subtracted from the average. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.
| letters | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Month 3 | 66.4 ± 10.66 | 59.2 ± 12.63 |
| Average Change from Baseline Month 4 to Month 12 | 0.3 ± 4.51 | 0.2 ± 6.08 |
Visual functioning was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in visual functioning, while a negative change value indicates a worsening.
| units on a scale | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 6 | 2.5 ± 13.54 | 0.5 ± 13.17 |
| Change from Baseline at Month 12 | 0.6 ± 14.99 | -0.4 ± 15.89 |
General health was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in general health, while a negative change value indicates a worsening.
| units on a scale | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 6 | -1.5 ± 22.32 | -0.4 ± 21.81 |
| Change from Baseline at Month 12 | -2.3 ± 24.34 | -4.3 ± 26.56 |
General vision was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in general vision, while a negative change value indicates a worsening.
| units on a scale | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 6 | 6.2 ± 18.77 | 4.7 ± 19.58 |
| Change from Baseline at Month 12 | 5.9 ± 18.12 | 5.9 ± 20.06 |
Color vision was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in color vision, while a negative change value indicates a worsening.
| units on a scale | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 6 | 2.0 ± 16.68 | 2.2 ± 17.26 |
| Change from Baseline at Month 12 | 0.2 ± 21.55 | 1.6 ± 20.35 |
Peripheral vision was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in peripheral vision, while a negative change value indicates a worsening.
| units on a scale | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 6 | 1.4 ± 20.51 | 5.5 ± 22.38 |
| Change from Baseline at Month 12 | -2.3 ± 25.07 | 3.1 ± 27.64 |
Ocular pain was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in ocular pain, while a negative change value indicates a worsening.
| units on a scale | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 6 | -1.5 ± 20.71 | 1.5 ± 20.89 |
| Change from Baseline at Month 12 | -0.3 ± 19.89 | 4.1 ± 22.72 |
Near activities were assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in near activities, while a negative change value indicates a worsening.
| units on a scale | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 6 | 5.6 ± 23.81 | -1.7 ± 24.20 |
| Change from Baseline at Month 12 | 0.6 ± 24.64 | -3.4 ± 21.93 |
Distance activities were assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in distance activities, while a negative change value indicates a worsening.
| units on a scale | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 6 | 5.4 ± 20.79 | -2.8 ± 19.35 |
| Change from Baseline at Month 12 | 1.6 ± 23.74 | -5.5 ± 21.89 |
Social functioning was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in social functioning, while a negative change value indicates a worsening.
| units on a scale | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 6 | 2.1 ± 19.24 | -1.5 ± 15.31 |
| Change from Baseline at Month 12 | -0.8 ± 21.58 | -3.2 ± 18.51 |
Mental health was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in mental health, while a negative change value indicates a worsening.
| units on a scale | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 6 | 1.8 ± 23.07 | -0.2 ± 23.58 |
| Change from Baseline at Month 12 | 1.3 ± 25.05 | 0.6 ± 23.32 |
Roles difficulties were assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in roles difficulties, while a negative change value indicates a worsening.
| units on a scale | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 6 | 1.4 ± 27.05 | -0.4 ± 24.24 |
| Change from Baseline at Month 12 | 0.4 ± 27.62 | -1.4 ± 28.36 |
Dependency was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in dependency, while a negative change value indicates a worsening.
| units on a scale | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 6 | 0.2 ± 27.95 | -4.3 ± 27.53 |
| Change from Baseline at Month 12 | 0.9 ± 30.47 | -5.3 ± 27.87 |
Driving was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in driving, while a negative change value indicates a worsening. Note: Many patients did not answer the driving related question as they did not drive at all.
| units on a scale | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Change from Baseline at Month 6 | 2.8 ± 15.87 | 2.8 ± 20.52 |
| Change from Baseline at Month 12 | -0.2 ± 12.29 | 4.5 ± 27.98 |
A ranibizumab re-treatment was defined as an administration of ranibizumab injection at a scheduled visit following at least one non-missed visit where ranibizumab was not administered in the study eye due to visual acuity stabilization. This outcome measure was pre-specified for the Ranibizumab 0.5 mg arm only.
| retreatments | Ranibizumab (RFB002) |
|---|---|
| Mean Number of Ranibizumab Re-treatments Received in the Study Eye From Month 3 Onward | 1.6 ± 0.64 |
Collected over Day 1 through study completion, an average of 1 year. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab (RFB002) | — | 57/307 (18.6%) | 116/307 (37.8%) |
| Laser | — | 15/75 (20%) | 30/75 (40%) |
| Event | Ranibizumab (RFB002) | Laser |
|---|---|---|
| Diabetic retinal oedema (Fellow eye)Eye disorders | 1/307 | 2/75 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 4/307 | 2/75 |
| Diabetic footSkin and subcutaneous tissue disorders | 1/307 | 2/75 |
| Coronary artery diseaseCardiac disorders | 5/307 | 0/75 |
| Diabetic nephropathyRenal and urinary disorders | 5/307 | 1/75 |
| Retinal detachment (Fellow eye)Eye disorders | 0/307 | 1/75 |
| Vitreous haemorrhage (Fellow eye)Eye disorders | 3/307 | 1/75 |
| Vitreous haemorrhage (Study eye)Eye disorders | 0/307 | 1/75 |
| AscitesGastrointestinal disorders | 0/307 | 1/75 |
| Hepatic cirrhosisHepatobiliary disorders | 0/307 | 1/75 |
| Event | Ranibizumab (RFB002) | Laser |
|---|---|---|
| HypertensionVascular disorders | 17/307 | 9/75 |
| NasopharyngitisInfections and infestations | 20/307 | 7/75 |
| Upper respiratory tract infectionInfections and infestations | 26/307 | 2/75 |
| CoughRespiratory, thoracic and mediastinal disorders | 18/307 | 2/75 |
| Alanine aminotransferase increasedInvestigations | 3/307 | 4/75 |
| Intraocular pressure increased (Study eye)Investigations | 16/307 | 0/75 |
| Urinary tract infectionInfections and infestations | 15/307 | 3/75 |
| Vitreous haemorrhage (Fellow eye)Eye disorders | 11/307 | 3/75 |
| Vitreous haemorrhage (Study eye)Eye disorders | 5/307 | 3/75 |
| HyperlipidaemiaMetabolism and nutrition disorders | 9/307 | 3/75 |
| Age, Continuous(years) | Ranibizumab (RFB002) | Laser | Total |
|---|---|---|---|
| Mean | 58.6 ± 8.70 | 59.0 ± 9.19 | 58.7 ± 8.79 |
| Sex: Female, Male(Participants) | Ranibizumab (RFB002) | Laser | Total |
|---|---|---|---|
| Female | 168 | 38 | 206 |
| Male | 139 | 39 | 178 |
| Best Corrected Visual Acuity(letters) | Ranibizumab (RFB002) | Laser | Total |
|---|---|---|---|
| Mean | 59.6 ± 10.53 | 58.2 ± 9.43 | 59.3 ± 10.32 |
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Nov 2014 to primary completion in Jan 2017, 26 months.
Results were first posted in Feb 2019, 2 years after primary completion.
Of 17 phase 3 interventional studies under Vision Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 28. This study's 26 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab